KiraGen Bio Welcomes Investment from the Yuvaan Tiwari Foundation

KiraGen Bio is honored to announce an investment from the Yuvaan Tiwari Foundation, a leading advocate for breakthrough research in diffuse midline glioma (DMG), DIPG, and other fatal pediatric brain cancers.

The Foundation was established by Parvati and Satya Tiwari in memory of their son Yuvaan, who was diagnosed with DMG at age two and passed away at three after a courageous seven-month fight. Yuvi loved sunshine and the color yellow, and even on the grayest days, he would insist that “the sun will come out.” That spirit now drives the Foundation’s mission to accelerate the development of curative therapies for children facing these devastating diagnoses.

Through strategic research funding, impact investing, and direct support for affected families, the Yuvaan Tiwari Foundation has become one of the most impactful organizations in the pediatric brain tumor community. Their portfolio reflects a conviction that bold, well-executed science can change outcomes where progress has historically been limited.

KiraGen shares that conviction. Our KiraLOGIC platform is designed to engineer CAR-T cell therapies that remain functional within the highly suppressive tumor microenvironments that define glioblastoma and pediatric brain cancers. We believe durable responses require durable cells, and we are building the scientific foundation to make that possible.

We are deeply grateful for the Foundation’s partnership and proud to stand alongside a family channeling profound loss into meaningful action for patients and families who urgently need new options.

To learn more about the Yuvaan Tiwari Foundation, visit ytfoundation.org